Abstract:Abstract There are many autoimmune diseases where pathologic self T cells are the underlying cause of disease symptoms and progression. T cells are found at the site of tissue destruction, resulting not only in the exacerbation of disease, but also the release of self-epitopes in the context of inflammation resulting in the activation of additional T cell populations perpetuating disease. Published data have shown treatment with antigen-containing biodegradablepoly(lactide-co-glycolide) (PLGA) nanoparticles, i.e. tolerogenic immune-modifying particles (TIMP), is both safe and induces antigen-specific tolerance in mouse models of autoimmunity and allergy, as well as in a celiac disease Phase I/IIa clinical trial. This study further investigated the role and mechanism of TIMP-induced tolerance. The present data show that TIMP treatment modulated T cells specific for spread epitopes associated with disease progression, but not encapsulated within the TIMP, i.e. tissue-specific bystander suppression. The PLP139–151 TCR transgenic model systems was utilized to determine the cellular and molecular mechanisms driving antigen specific tolerance mediated by tolerogenic nanoparticle treatment. These data show antigen-specific TIMP treatment induced both FoxP3+ iTregs and IL-10+ Tr1 regulatory phenotypes within the antigen-specific T cell populations in both naïve mice and mice pre-primed with antigen/CFA. Additionally, both functional Tregs and IL-10 are required for TIMP-induced tolerance. Treatment thus activates various antigen-specific Treg subsets capable of regulating responses to disease-relevant autoepitopes not encapsulated within the TIMP via release of immunoregulatory cytokines within the inflammatory site. Supported by funding provided by Cour Pharmaceuticals Development, Inc.

Nanomaterials for antigen-specific immune tolerance therapy

Cationic nanoparticles-based approaches for immune tolerance induction in vivo

Nanoparticle-Based Drug Delivery Systems for Induction of Tolerance and Treatment of Autoimmune Diseases

Antigen‐specific Mrna Lipid Nanoparticle Platforms for the Prevention and Treatment of Allergy and Autoimmune Diseases

Tolerogenic Nano-/Microparticle Vaccines for Immunotherapy.

Polymer Nanotherapeutics to Correct Autoimmunity

Tolerogenic Vehicles of Antigens in the Antigen-Specific Immunotherapy for Autoimmunity

Peptide-Conjugated Nanoparticles Reduce Positive Co-stimulatory Expression and T Cell Activity to Induce Tolerance

Advances in dendritic cell targeting nano-delivery systems for induction of immune tolerance

Application of nanotechnology in circumventing immunotolerance.

Progress in Nanoparticle-Based Regulation of Immune Cells.

Nanomaterials as Smart Immunomodulator Delivery System for Enhanced Cancer Therapy

Bioconjugate Strategies for the Induction of Antigen-Specific Tolerance in Autoimmune Diseases

Antigen-specific nanoparticle tolerance treatment actively induces both FoxP3- and IL-10-dependent regulatory mechanisms

Liver-Targeting Nanoplatforms for the Induction of Immune Tolerance

An Overview of Nanotechnological Approaches for the Diagnosis and Treatment of Allergic Illness

Nanomaterials-involved strategies for reversing the immunosuppressive factors and improving antitumor immunotherapy

Lymphoid organ-targeted nanomaterials for immunomodulation of cancer, inflammation, and beyond

Low-dimensional nanomaterials enabled autoimmune disease treatments: Recent advances, strategies, and future challenges

Tailoring the Physicochemical Properties of Nanomaterials for Immunomodulation.

Application of nanomaterials in cancer immunotherapy